NeuroBo Pharmaceuticals(NRBO) - 2025 Q3 - Quarterly Results

Exhibit 99.1 MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update Dosed the First Patient in the 8-Week 48 mg MAD Cohort of its Phase 1 Clinical Trial to Further Explore Non-Titrated Maximum Tolerated Dose of DA- 1726 for the Treatment of Obesity; Top-Line Data Expected by Year-End 2025 $14.3 Million in Cash at End of Third Quarter is Expected to Fund the Company Into 2026 CAMBRIDGE, Mass., November 6, 2025 – MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company f ...